Business
Can-Fite: Receives Canadian Patent Allowance for Namodenoson as an Anti-Obesity Therapy
Namodenoson’s oral safety profile and metabolic activity, position it as a promising candidate in the rapidly growing obesity treatment market Ramat Gan, Israel, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that the Canadian Patent Office has issued a notice of allowance for Canadian Patent Application
About this update from Can-fite Biopharma Ltd.
[{"type":"image","alt":"Can-Fite BioPharma Ltd.","displaySize":"","headline":null,"caption":"Can-Fite BioPharma Ltd.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":300,"url":"https://media.zenfs.com/en/globenewswire.com/58ba4a28406cb6448f12deb3b1c1ba75"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/lgDBemc5K_V72t9MXF.pPA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTQyMDtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/58ba4a28406cb6448f12deb3b1c1ba75","width":300,"height":300}},"lazy":false},{"type":"text","content":"Namodenoson’s oral safety profile and metabolic activity, position it as a promising candidate in the rapidly growing obesity treatment market","length":142,"tagName":"p"},{"type":"text","content":"Ramat Gan, Israel, Feb. 09, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE:CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, today announced that the Canadian Patent Office has issued a notice of allowance for Canadian Patent Application No. 3,126,002, titled “An A3 adenosine receptor ligand for use for achieving a fat loss effect.","length":453,"tagName":"p"},{"type":"text","content":"The patent covers the use of Namodenoson, Can-Fite’s orally bioavailable A3 adenosine receptor (A3AR) agonist, for reducing fat mass and body weight, providing intellectual property protection in Canada for its development as an anti-obesity therapy.","length":250,"tagName":"p"},{"type":"text","content":"Can-Fite already holds corresponding patents in the United States and Australia for the use of Namodenoson in obesity and metabolic disorders. Namodenoson is currently in clinical development for Metabolic Dysfunction-Associated Steatohepatitis (MASH), advanced liver cancer, and pancreatic cancer, and has demonstrated an excellent safety profile across multiple clinical studies following oral administration.","length":411,"tagName":"p"},{"type":"text","content":"The anti-obesity patent application is based on data demonstrating that treatment of fat cells with Namodenoson reduced fat levels via the increase of the hormone adiponectin, a regulator of fat production in the body. Namodenoson also reduced body weight in an experimental animal model of obesity, induced by high fat diet. In a MASH Phase IIa ...